Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction

Heart

Volumn 99, Issue 11, 2013, Pages 767-773

  O'Brien, Emily C ^a   Rose, Kathryn M ^a,b   Suchindran, Chirayath M ^a   Stürmer, Til ^a   Chang, Patricia P ^c   Chambless, Lloyd ^a   Guild, Cameron S ^d   Rosamond, Wayne D ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b SRA International Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COMMUNITY CARE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STENT; SURVIVAL;

MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD);

ADULT; AGED; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; STENTS; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84877599756     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303244     Document Type: Article

References (27)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
2. Floyd KC, Yarzebski J, Spencer FA, et al. A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes 2009;2:88-95.
3. Fox CS, Evans JC, Larson MG, et al. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation 2004;110:522-7. (Pubitemid 39031167)
4. Gale CP, Cattle BA, Woolston A, et al. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. Eur Heart J 2012;33:630-9.
5. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98. (Pubitemid 46883773)
6. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268:1417-22.
7. Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73. (Pubitemid 46072409)
8. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365:82-93. (Pubitemid 40082150)
9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-63. (Pubitemid 27446562)
10. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the atherosclerosis risk in communities (ARIC) study: Methods and initial two years' experience. J Clin Epidemiol 1996;49:223-33. (Pubitemid 26123934)
11. Rosamond WD, Chambless LE, Sorlie PD, et al. Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. American Journal of Epidemiology 2004;160:1137-46. (Pubitemid 39628053)
12. Westreich D, Cole SR. Invited commentary: positivity in practice. Am J Epidemiol 2010;171:674-7; discussion 678-681.
13. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
14. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Patient population. Am J Cardiol 1985;56:10G-14G.
15. Antithrombotic Trialists' Collatoration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
16. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. The Israeli Sprint Study Group. Eur Heart J 1988;9:354-64.
17. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100, 000 patients in randomized trials. Circulation 1998;97:2202-12.
18. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
19. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9. (Pubitemid 26338729)
21. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
22. Chua D, Lo C, Babor EM. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction. N Engl J Med 2005;352:2647-8; author reply 2647-8. (Pubitemid 41007855)
23. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-56. (Pubitemid 30010402)
24. Wilson SH, Bell MR, Rihal CS, et al. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001;141:704-10. (Pubitemid 32378477)
25. Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol 2000;35:1729-36. (Pubitemid 30342850)
26. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-81. (Pubitemid 41132680)
27. Feinstein AR. Current problems and future challenges in randomized clinical trials. Circulation 1984;70:767-74. (Pubitemid 15205439)